Boston Scientific (BSX) – Analysts’ Weekly Ratings Changes

Boston Scientific (NYSE: BSX) recently received a number of ratings updates from brokerages and research firms:

• 10/20/2026 – Boston Scientific had its “buy” rating reaffirmed by TD Cowen.
• 10/14/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $57.00 to $51.00. They now have a “buy” rating on the stock.
• 10/13/2026 – Boston Scientific was given a new $55.00 price target by Mizuho.
• 10/9/2026 – Boston Scientific had its price target lowered by Leerink Partners from $60.00 to $55.00.
• 10/7/2026 – Boston Scientific had its price target lowered by Evercore Inc from $65.00 to $52.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Boston Scientific was upgraded by Barclays PLC to “hold”.
• 10/6/2026 – Boston Scientific is now covered by Barclays PLC. They set an “equal weight” rating and a $48.00 price target on the stock.
• 10/5/2026 – Boston Scientific had its price target lowered by Citigroup Inc. from $50.00 to $48.00. They now have a “neutral” rating on the stock.
• 10/3/2026 – Boston Scientific had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $54.00 price target on the stock, down from $60.00.
• 10/2/2026 – Boston Scientific had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 9/23/2026 – Boston Scientific had its price target lowered by Wells Fargo & Company from $50.00 to $48.00. They now have an “equal weight” rating on the stock.
• 9/21/2026 – Boston Scientific had its price target lowered by Oppenheimer Holdings, Inc. from $85.00 to $65.00. They now have an “outperform” rating on the stock.
• 9/17/2026 – Boston Scientific had its “buy” rating reaffirmed by TD Cowen.
• 9/17/2026 – Boston Scientific was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $50.00 price target on the stock, down from $57.00.
• 9/9/2026 – Boston Scientific had its price target lowered by BTIG Research from $60.00 to $56.00. They now have a “buy” rating on the stock.
• 8/25/2026 – Boston Scientific had its “buy” rating reaffirmed by TD Cowen. They now have a $56.00 price target on the stock.

Insider Buying and Selling

In related news, Director David C. Habiger acquired 2,100 shares of the stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 194,522 shares of company stock valued at $9,385,210 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.